FDMT4D Molecular Therapeutics, Inc.

$468M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-43.4% YoY

Gross Profit

-$11M-538.5% margin

Operating Income

-$16M-815.6% margin

Net Income

-$16M-820.3% margin

EPS (Diluted)

$-0.61

QoQ Revenue Growth

+304.7%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$16M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$270M

Total Liabilities

$28M

Stockholders' Equity

$242M

Cash & Equivalents

$260M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$4M	-43.4%
Gross Profit	-$11M	-$10M	-11.9%
Operating Income	-$16M	-$13M	-22.9%
Net Income	-$16M	-$13M	-24.7%

Geographic Segments

SWITZERLAND

$2M80%

NETHERLANDS

$392,00020%

UNITED STATES

$3,0000%

FDMT Q1 2021 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena